GlassScriptPhysician profile
Kiranmayi Chilappa
NPI 1366551533
$5,457.91
in general payments reported to CMS, 2019-2025
30 companies · $757 in 2025
The $757 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $361 · 2021: $913 · 2022: $589 · 2023: $767 · 2024: $1,820 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276 · Travel and Lodging: $1,036 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.09 |
| Travel and Lodging | $1,036.20 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,310.78 | 2020-2025 | Triclip, Epic |
| Amgen INC. | $469.91 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $432.49 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $380.02 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $346.75 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $315.97 | 2019-2025 | |
| Boston Scientific Corporation | $303.19 | 2020-2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $242.74 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $234.30 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $217.60 | 2019-2025 | Wainua |
| Lantheus Medical Imaging, INC. | $187.86 | 2020-2025 | Definity |
| Novo Nordisk INC | $143.64 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $127.32 | 2021-2025 | Lifevest |
| Angiodynamics, INC. | $104.46 | 2020 | |
| Astellas Pharma US INC | $101.15 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.43 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $70.43 | 2022-2025 | |
| Irhythm Technologies, INC. | $63.14 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Alnylam Pharmaceuticals INC. | $49.27 | 2019-2021 | |
| Philips North America LLC | $48.07 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $44.91 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $27.36 | 2021-2022 | |
| Genzyme Corporation | $25.78 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $21.99 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $21.80 | 2025 | Nexletol |
| Blue Earth Diagnostics | $20.64 | 2024 | |
| Amryt Pharma Holdings LTD | $17.68 | 2021 | |
| Medtronic, INC. | $16.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.60 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiranmayi Chilappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.